Myo-inositol supplementation for prevention of gestational diabetes mellitus in overweight and obese pregnant women: a systematic review and meta-analysis

Mashayekh-Amiri, Sepideh; Mohammad-Alizadeh-Charandabi, Sakineh; Abdolalipour, Somaiyeh; Mirghafourvand, Mojgan

doi:10.1186/s13098-022-00862-5

Table 2 Use of the Myoinositol versus Placebo

From: Myo-inositol supplementation for prevention of gestational diabetes mellitus in overweight and obese pregnant women: a systematic review and meta-analysis

No. of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Use of the MI	No Use of the MI	Pooled effect Relative^a [95% CI]	Final judgment
Gestational diabetes rate [GDM Rate]
4	RCTs	Serious^b	No serious	No serious	No serious	No serious	38/339	99/351	OR 0.32 [0.21 to 0.]48]	⨁⨁⨁Ο MODERATE
FG-OGTT
4	RCTs	Serious^b	No serious	No serious	No serious	No serious	339	351	MD 2.64 lower [4.12 to 1.17 lower]	⨁⨁⨁Ο MODERATE
1 h-OGTT
4	RCTs	Serious^b	No serious	No serious	No serious	No serious	339	351	MD 7.47 lower [12.24 to 2.31 lower]	⨁⨁ΟΟ LOW
2 h-OGTT
4	RCTs	Serious^b	Serious²	No serious	No serious	No serious	339	351	MD 10.51 lower [16.88 to 4.14 lower]	⨁⨁ΟΟ LOW
Gestational hypertension
4	RCTs	Serious^b	No serious	No serious	No serious	No serious	9/339	35/351	OR 0.26 [0.13 to 0.56]	⨁⨁⨁Ο MODERATE
Preterm labor
3	RCTs	Serious^b	No serious	No serious	Serious^d	No serious	7/229	21/238	OR 0.33 [0.14 to 0.81]	⨁⨁ΟΟ LOW
Cesarean section rate
3	RCTs	Serious^b	No serious	No serious	Serious^d	No serious	97/229	116/238	OR 0.77 [0.53 to 1.12]	⨁⨁ΟΟ LOW
Macrosomia
3	RCTs	Serious^b	No serious	No serious	Serious^d	No serious	8/229	12/238	OR 0.74 [0.28 to 1.95]	⨁⨁ΟΟ LOW
Neonatal hypoglycemia
2	RCTs	Serious^b	No serious	No serious	Very serious^d	No serious	0/202	2/209	OR 0.34 [0.04 to 3.32]	⨁ΟΟΟ VERY LOW
NICU admission
3	RCTs	Serious^b	No serious	No serious	Serious^d	No serious	3/229	11/238	OR 0.36 [0.10 to 1.32]	⨁⨁ΟΟ LOW
Shoulder dystocia
3	RCTs	Serious^b	No serious	No serious	Very serious^d	No serious	1/229	2/238	OR 0.64 [0.08 to 5.25]	⨁ΟΟΟ VERY LOW

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
CI confidence interval, OR odds ratio, OGTT oral glucose tolerance test, NICU neonatal intensive care unit admission
^aThe risk in the intervention group [and its 95% confidence interval] is based on the assumed risk in the comparison group and the relative effect of the intervention [and its 95% CI]
^bStudies at high risk of bias
^cSevere unexplained heterogeneity
^dWide confidence interval [CI] crossing the line of no effect
^eSmall sample size and/or few events

Back to article page

ISSN: 1758-5996

Contact us

Submission enquiries: journalsubmissions@springernature.com

Diabetology & Metabolic Syndrome

Contact us